Purpose: To improve the cost efficiency of the imaging evaluation of clinically suspected pheochromocytoma by using 24-hour fractionated urine metanephrine (FUM) results. Methods: A retrospective review of I-123 meta-iodo-benzyl-guanidine single photon emission tomography (SPECT) computed tomography (CT) studies performed at our institution between January 2007 and February 2011 for clinically suspected pheochromocytoma was performed. SPECT-CT results from 70 patients were compared with results from 24-hour FUM analysis (within 2 months of SPECT-CT) and with relevant CT or magnetic resonance imaging studies (within 6 months of SPECT-CT). An imaging algorithm was developed to maximize cost efficiency without altering the final imaging interpretation. Actual imaging costs for the studied cohort were compared with the expected costs if this algorithm had been applied. Results: If the 24-hour FUMs were normal, then all the SPECT-CT studies were negative (16/70). Eighty-seven percent of patients with abnormal total metanephrine had a positive SPECT-CT. If the total metanephrine was normal but 1 or more of the metanephrine fractions were abnormal, then 39%-58% of the SPECT-CT studies were positive. Within this subgroup, none had a positive SPECT-CT if a CT or magnetic resonance image was negative or benign. The actual imaging costs averaged CAD$2833.19 per patient for this cohort. Applying a streamlined imaging algorithm guided by 24-hour FUM analysis would result in an average imaging cost of CAD$1225.97 per patient without an expected change in the final imaging impression. Conclusion: By using 24-hour FUM results to streamline imaging, considerable cost savings per patient (56.7%) can be attained without a change in the final overall imaging interpretation.
Pheochromocytomas (intra-adrenal paragangliomas) are rare neuroendocrine neoplasms that arise from chromaffin cells of the adrenal medulla [1] . The prevalence of pheochromocytoma is estimated to be approximately 0.1%-0.6% of patients with hypertension [2] , with an annual incidence of approximately 2-8 per million persons per year [3] . Pheochromocytomas produce catecholamines, including epinephrine, norepinephrine, and/or dopamine, which are then metabolized primarily intratumourally to form metanephrines [4] . The clinical symptomatology that results from the production of catecholamines and/or metanephrines is nonspecific and variable. The classic clinical triad includes headaches, excessive sweating, and palpitations and/or tachycardia; however, this only occurs in 10%-36% of patients [5, 6] . Other symptoms include paroxysmal or sustained hypertension, fatigue, weight loss, hyperglycemia, pallor, and nausea. Pheochromocytomas should be considered in patients with classic symptomatology, discovery of a suspicious incidental adrenal mass or in a patient with familial disease. The majority of diagnosed cases are sporadic; however, at least 25% of cases may be associated with familial diseases such as von Hippel-Lindau disease, multiple endocrine neoplasia type 2, neurofibromatosis type 1, or succinate dehydrogenase mutation [7] .
For clinically suspected pheochromocytomas, the first diagnostic examination performed is typically a biochemical assessment for excess catecholamines or metanephrines. Commonly, these include 24-hour fractionated urine metanephrines (FUM) (with or without vanillylmandelic acid), total plasma metanephrines (metanephrine and normetanephrine), and plasma concentration of free metanephrines. The decision of which biochemical test to use is debated and variable among institutions, and a general consensus has not been established [8e10]. FUMs typically measure the 24hour urinary excretion of metanephrine (metabolite of epinephrine), normetanephrine (metabolite of norepinephrine), 3-methoxytyramine (metabolite of dopamine), and the total concentration of metanephrines. The sensitivity of FUMs is high and ranges from 90%-97%, with a specificity that ranges from 69%-98% [8e10]. Generally, biochemical tests for pheochromocytomas have a high negative predictive value, of approximately 95%-100% [11] . Given the low incidence and prevalence of pheochromocytoma, the positive predictive value is generally low and difficult to accurately determine given varying pretest probabilities [10] . This leads to a high rate of false-positive results, which necessitates the need for additional tests. After a positive biochemical analysis, an imaging examination is often performed to improve specificity.
Several imaging methods are available for further evaluation of clinically suspected pheochromocytoma, including anatomic imaging modalities such as computed tomography (CT) and magnetic resonance imaging (MRI) as well as functional imaging modalities such as I-123/I-131 metaiodo-benzyl-guanidine (MIBG) [12e15]. Given the highly variable appearance of pheochromocytomas, anatomic imaging modalities have high sensitivities but lower specificities. When compared with anatomic imaging, functional imaging is generally more specific (95%-100%); however, its sensitivity is more limited (77%-90%) [16, 17] . Additional strengths of functional whole-body imaging methods include assessment of extra-adrenal pheochromocytomas, metastatic disease, and/or tumour recurrence.
With the recent introduction of hybridized single photon emission tomography CT (SPECT-CT) technology, anatomic and functional imaging modalities are combined maximizing sensitivity and specificity [18e20]. As such, this imaging method has become a common imaging technique used in patients suspected of having a pheochromocytoma after a positive biochemical analysis; however, an exact association between the quantitative biochemical parameters and imaging findings has not been established. Given the low positivepredictive value of elevated urine metanephrines and the relatively high cost of I-123 MIBG SPECT-CT, it is likely not cost efficient to perform this imaging study on every patient with this biochemical abnormality. In clinical practice, these patients also are often imaged in a nonlinear fashion (ie, ''shotgun approach'') and receive multiple imaging tests, including CT, MRI, and/or SPECT-CT, which further increases imaging costs. When considering this, the goal of our study was to develop a cost-efficient approach to imaging clinically suspected pheochromocytoma by using the FUM results to streamline our approach.
Materials and Methods

Study Design and Study Population
A retrospective chart review of all patients who had an I-123 MIBG SPECT-CT study between January 2007 and February 2011 was performed. The protocol was reviewed and approved by our institutional research ethics board. All SPECT-CTs were supervised and interpreted by trained licensed specialists in nuclear medicine in accordance with standard clinical practice. Based on a review of the imaging reports, the results were recorded as positive, negative, or nondiagnostic for pheochromocytoma. The 24-hour FUM results that were closest to the date of the SPECT-CT (within 2 months) were recorded. Any relevant CT and/or MRI reports within 6 months of the SPECT-CT also were reviewed. These were recorded as either normal-benign, nonspecificnondiagnostic, or suspicious for pheochromocytoma. Patients were excluded if the SPECT-CT was performed for suspected recurrence of pheochromocytoma, assessment of known pheochromocytoma for metastatic disease, or followup of previously treated pheochromocytoma. Patients were excluded if the SPECT-CT was performed for indications other than clinically suspected pheochromocytoma or if the patient had not had 24-hour FUM analysis within 2 months of the SPECT-CT. Pregnant patients and patients <18 years old also were excluded from analysis.
The recorded 24-hour FUM values included total metanephrine (TMET) (reference value, <1.7 mmol per 24 hours), total normetanephrine (TNOR) (reference value, <2.6 mmol per 24 hours), total 3-methoxytyramine (T3M) (reference value, <1.3 mmol per 24 hours), and total metanephrines, total (TMTOT), which is a summation of all the metanephrine fractions (TMET þ TNOR þ T3M ¼ TMTOT) (reference value, <5.6 mmol per 24 hours). Regionally, these were obtained clinically by using high-performance liquid chromatography methodology (Bio-Rad, Hercules, CA). The results for each of the FUM values and all combinations of 2, 3, or 4 of the metanephrine fractions were then tabulated based on whether the SPECT-CT was positive or negative for pheochromocytoma for each individual patient. Interpretations categorized as nondiagnostic were considered negative for the purposes of this study (no actionable proof of pheochromocytoma).
A diagnostic imaging algorithm was then developed by using the 24-hour FUM results to guide the need for further imaging (if any) and aid in the decision of which imaging modality would be appropriate, with the goal of minimizing imaging costs while maintaining the same final diagnostic imaging interpretation. The actual imaging costs for the study cohort were then compared with the expected costs by using the developed algorithm.
Imaging Techniques: Our Standard Institutional Imaging Protocols
SPECT-CT
A total of 400 MBq I-123 MIBG is injected slowly over 10 minutes. Both planar and SPECT-CT images are acquired 24 hours after the injection of I-123 MIBG. Lugol solution, 0.8 mL, is administered orally in juice 2 hours before the injection of I-123 MIBG, with an additional administration on the day of imaging. A photopeak is set for I-123 (159 keV with a 20% window). Whole-body planar imaging (head to mid thigh) is obtained at 8 cm/min with low-energy highresolution collimators, followed by 1,000,000 count or 20minute anterior-posterior images of the abdomen (whichever is shorter). SPECT-CT images of the abdomen are acquired with a 16-slice SPECT-CT camera (Philips Precedence, Best, the Netherlands). SPECT parameters used include 128 frames at 40 seconds per frame, with a total rotation of 360 . SPECT images are processed by using iterative reconstruction with resolution recovery (Astonish; 4 iterations and 16 subsets). Acquisition parameters for the CT component of these studies are as follows: 16 Â 1.5 mm collimation, 0.5-second gantry rotation time, 0.938 pitch, 600-mm field of view, 512 Â 512 matrix size, 140 kVp, and 50 mAs. Iodinated intravenous contrast is not administered. The images reported for these studies are interpreted by trained nuclear medicine specialists by using the Extended Brilliance Workstation software (Philips, Best, the Netherlands).
CT Adrenals
Imaging is performed by using a variety of multidetectorrow CT scanners (16-320 slice, various vendors). For all scans, the scan range extends from the diaphragmatic crus to include both adrenal glands. The photon energy is typically 120 kVp, with the mAs determined by using various dose modulation applications. The standard adrenal mass protocol is unenhanced, with no oral or intravenous contrast administered.
MRI Adrenals
Imaging is performed by using a variety of 1.5T wholebody MRI scanners (various vendors). For all studies, a body matrix coil is used over the upper abdomen. The typical adrenal mass protocol includes T1-weighted imaging with fat saturation (before gadolinium followed by 30 seconds, 60 seconds, and 300 seconds after gadolinium), T2-weighted imaging, diffusion-weighted imaging, and gradient echo sequences with both in-phase and opposed-phase imaging.
Cost Estimates
The operational costs, in Canadian dollar equivalents per imaging examination, were determined based on radiotracer costs, intravenous contrast costs, interpretation fees, imaging staff costs, medical supplies, booking services, and transcription services. The costs associated with each imaging test are as follows: I-123 MIBG SPECT-CT, CAD$2554.71 (tracer cost, CAD$2110.50 per dose); nonaugmented CT adrenal, CAD$153.35; and MRI adrenal, CAD$305.47 (Table 1) .
Imaging system costs were not included in this cost estimate. The number of scans for this clinical indication are low relative to overall system use. For example, the involved institution typically performs approximately 10,000 CTs, 10,000 MRIs, and 1000 SPECT-CT studies per camera annually. As such, the impact of this clinical indication in the decision to purchase these imaging systems is negligible and can be excluded from the assessment.
Results
Study Cohort
A total of 183 SPECT-CTs (157 patients) were performed during the study period. Eighty-seven patients were excluded from the study, including 38 for not having a urinary metanephrine assessment within 2 months of the SPECT-CT; 15 for assessment of pheochromocytoma recurrence or metastases; 7 for a complete lack of urinary metanephrine biochemical assessment; 23 for study indications other than for pheochromocytoma, such as other neuroendocrine tumours; 2 patients for incomplete data; and 2 patients for therapy planning. These exclusions included 3 patients who had known syndromes associated with pheochromocytoma (2 patients with von Hippel-Lindau disease and 1 patient with multiple endocrine neoplasia 2a). On review of the provided clinical histories, none of the included patients had a known family history of pheochromocytoma or a known syndrome associated with pheochromocytoma.
A total of 70 patients were ultimately eligible for the study, which accounted for a total of 72 SPECT-CT examinations, 44 CTs, and 25 MRIs. This resulted in an average imaging cost per patient of CAD$2833. 19 . Two of the patients had more than 1 SPECT-CT study. The reasons for the repeated SPECT-CTs included persistent clinical suspicion due to patient symptomatology and biochemical values (n ¼ 1), and after an incomplete SPECT-CT examination (n ¼ 1). For these patients, both SPECT-CT examinations were included for the purposes of cost analysis; however, for the purposes of creating an algorithm by using the 24-hour FUM measurements and for the analysis of the SPECT-CT results, only completed studies and/or the study closest temporally to the date of the 24-hour FUM collection were included. Of the SPECT-CTs analysed, 25.7% (18/70) were positive, 65.7% (46/70) were negative, and 8.6% (6/70) were nondiagnostic or incomplete for pheochromocytoma. The reasons for nondiagnostic examinations varied and included patient factors such as cooperation, insufficient counts, and difficulty differentiating between hyperplasia and early and/or lowgrade neoplasm.
Normal TMET, TNOR, T3M, and TMTOT
If all of the measured urinary metanephrine values were normal, then none of the SPECT-CT studies were positive. This occurred in 22.3% of patients (16/70).
Abnormal TMET
An abnormal TMET fraction had the highest association with a positive SPECT-CT study. Seventeen patients (17/70) had abnormal TMET values. Of these, 87% (15/17) had a positive SPECT-CT. The percentage of patients with a positive SPECT-CT increased further when additional metanephrine fractions were abnormal in combination with an abnormal TMET. Twelve patients (12/17) had both TMET and TNOR fractions elevated. Ninety-two percent of these patients (11/12) had a positive SPECT-CT. If both the TMET and T3M fractions were elevated (8/17), then 100% of the SPECT-CTs were positive. Of the patients in whom the TMET and TMTOT values were abnormal (15/17), 87% (13/ 15) had a positive SPECT-CT (Figure 1 ).
Normal TMET but Other Abnormal Fraction
Overall, only 12% of the patients with a normal TMET (6/ 53) had a positive SPECT-CT. The positive SPECT-CT rate increased if the TMET was normal and one or a combination of the other metanephrine fractions and/or the TMTOT fraction were abnormal. A total of 39%-58% of these patients had a positive SPECT-CT. If these patients also had a negative or benign CT or MRI, however, then none had a positive SPECT-CT (Table 2) . 
CT and MRI
Seventy
Imaging Algorithm
Based on these data, a diagnostic imaging algorithm for clinically suspected pheochromocytoma was developed with the goal of maximizing cost efficiency while not altering the final imaging interpretation (Figure 2 ). If this proposed algorithm was applied to our study population, then the number of SPECT-CT examinations would be reduced from 72 to 30, the number of CTs from 42 to 20, and the number of MRIs from 26 to 20 (an equal number of CT and MRI 
Discussion
The diagnosis of pheochromocytoma remains difficult given its nonspecific and variable clinical presentation in combination with its low incidence and prevalence. Biochemical examinations remain appropriate first-line investigations for clinically suspected pheochromocytomas given their high sensitivity. Limited specificity, low positive predictive value, and the inability to localize disease dictates the need for further investigatory methods with imaging. Anatomic imaging methods such as CT or MRI are also very sensitive for adrenal-based pheochromocytomas, however lack specificity. In our study population, 50% of the anatomic imaging interpretations were nonspecific or nondiagnostic, which ultimately required additional imaging with a SPECT-CT. SPECT-CT combines the high sensitivity of CT with the high specificity of MIBG; however, the costs associated with the examination are substantially higher than the other imaging methods.
The goal of our study was to develop an algorithm that used 24-hour urine metanephrine data to streamline imaging for this clinical problem in an attempt to minimize cost. It should be stressed that the intent of this study was not to define the accuracy of the individual imaging investigations (CT, MRI, and/or I-123 MIBG SPECT-CT) but to attempt to create a logical cost-saving algorithm for the assessment of clinically suspected pheochromocytoma rather than a ''shotgun'' approach to imaging. Our proposed algorithm is outlined in Figure 1 . If the metanephrine values are normal, then no additional imaging is required given that none of these patients in our study had a positive SPECT-CT (both SPECT and CT components were negative). If the TMET fraction is abnormal, then the patient should have a SPECT-CT examination as the primary imaging test because 87% of patients (13/15) with an abnormal TMET have a positive SPECT-CT. If the TMET is normal but one or a combination of the other metanephrine fractions or the summation of the metanephrines (TMTOT) was abnormal, then the patient should proceed to a CT or an MRI of the adrenals for initial imaging evaluation. For these patients, if the CT or MRI is definitively benign (ie, adenoma or myelolipoma) or normal, then no further imaging is required; none of these patients had a positive SPECT-CT. If the CT or MRI is not negative or benign, however, then a SPECT-CT should be performed. By using the algorithm, the potential cost savings are substantive, while maintaining the same diagnostic imaging assessment. This algorithm allows for the reduction of additional and overlapping imaging investigations, reduced radiation exposure, more streamlined investigation, and improved cost-effectiveness. Overall, a cost savings of 56.7% per patient could be achieved without a change in diagnostic imaging interpretation. Our algorithm recommends no imaging in patients with completely normal urine metanephrines. Although this may be logical based on the known high sensitivity of urine metanephrines for pheochromocytoma, in practice, imaging is performed in some of these patients. In our cohort of 70 patients, 16 patients had an I-123 SPECT-CT despite entirely normal urine metanephrine fractions. It is understandable that in clinical practice there may be situations in which the referring clinician might be uncomfortable with a lack of further imaging investigations in a patient with a high clinical suspicion for pheochromocytoma and negative urine metanephrines. In this setting, under consultation with a radiologist, a CT or an MRI may be appropriate to exclude an adrenal mass. Even when assuming that all of these patients in our study population (n ¼ 16) received either a CT or an MRI (assumed equal distribution, 8 CT and 8 MRI studies), the average cost per patient would be CAD$1278.40 per patient, for a savings of 54.9% compared with the actual imaging costs for the cohort.
For patients with a normal TMET but other abnormal urinary metanephrine fractions, our algorithm recommends only CT or MRI initially. A following SPECT-CT study should only be performed if the anatomic imaging is not negative or benign (definitive adenoma or myelolipoma).
The potential exists to miss extra-adrenal paragangliomas in these patients. Although, classically, the incidence of extraadrenal paraganglioma is noted at 10%, the true incidence of this abnormality in patients without a genetic predisposition has recently come into question. The classic ''10% rule' dates back to at least the early 1950s, which represents a patient population presenting at a much later stage in the course of disease than modern clinical populations [21] . A large portion of these patients would have also had a genetic predisposition, which elevated the incidence of extra-adrenal disease in the overall group. For example, patients with succinate dehydrogenase B mutations (autosomal dominant) almost always present with extra-adrenal disease [7] . Once patients with a genetic predisposition (known family history of pheochromocytoma or paraganglioma) are excluded, the real incidence of extra-adrenal disease in modern presenting populations with a clinical question of pheochromocytoma may be less than 5% [7] . Interestingly, a very recent evaluation of a Canadian population of 53 patients with pathology proven pheochromocytoma demonstrated only 1 patient with extra-adrenal disease [22] .
Our study specifically does not include patients with a high pretest probability such as those with a family history of or a genetic predisposition to pheochromocytoma (including patients with von Hippel-Lindau disease, multiple endocrine neoplasia type 2, neurofibromatosis type 1, or known family history). This algorithm should not be applied to these specific groups. When considering this, the risk of missed isolated extra-adrenal disease with our algorithm is low (likely <5%). If this potential is of concern clinically, then easy steps to further decrease the risk would be to extend the CT or MRI to include the organ of Zuckerkandl (most common site of extraadrenal disease) or reassess the patient with follow-up FUMs to determine if the TMET becomes abnormal.
A limitation of this study is the lack of a criterion standard for assessing the accuracy of the diagnostic methods performed. The accuracies of these modalities in imaging pheochromocytoma has recently been reviewed elsewhere [23, 24] . The intent of our study was to streamline the approach to imaging rather than assessing the accuracy of the imaging modalities themselves. Another limitation of our study was that the algorithm is based on the use of 24-hour FUMs. Although this biochemical test is widely used and has a high sensitivity, it is not the only biochemical test in use, and a consensus over the appropriate biochemical test is controversial and varies by institution. Further studies that involve alternative biochemical investigations, such as plasma metanephrines, could yield an appropriate cost-efficient imaging algorithm by using SPECT-CT. A third limitation is that operational costs associated with our analysis reflect a local hospital-based imaging environment and local radiopharmaceutical costs. Because 82.6% (CAD$2110.50 per CAD$2554.71) of the I-123 MIBG SPECT-CT cost in our study cohort is related to the cost of the radiopharmaceutical, variations in this could have a marked impact on overall cost savings with our proposed imaging algorithm. The potential impact of this must be taken into consideration at a local level. Finally, there are limitations associated with the retrospective nature of the study and algorithm development. The feasibility of the application of the proposed algorithm in a prospective nature has not been assessed.
In conclusion, our proposed cost-saving algorithm for clinically suspected pheochromocytomas (Figure 1 ) uses the results from biochemical assessment of 24-hour FUMs to guide diagnostic imaging evaluation. Applying this algorithm to our patient cohort would streamline the use of functional and anatomic imaging as well as diminish duplicate testing, which results in a cost savings of 56.7% (CAD$1607.22) without affecting the final diagnostic imaging interpretation.
